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Abstract
Background: The year 2015 marked the end of United Nations Millennium Development Goals which was aimed
at halting and reversing worldwide tuberculosis (TB). The emergence of drug resistance is a major challenge for
worldwide TB control. The aim of this study was to give a bibliometric overview of publications on multi-,
extensively, and totally drug-resistant TB.
Methods: Scopus database was used to retrieve articles on multidrug resistant (MDR), extensively drug-resistant (XDR),
and totally drug-resistant (TDR) tuberculosis for the study period (2006–2015). The number of publications, top
productive countries and institutions, citation analysis, co-authorships, international collaboration, active authors, and
active journals were retrieved and analyzed.
Results: A total of 2260 journal articles were retrieved. The mean ± SD citations per article was 7.04 ± 16.0. The h-index
of retrieved data was 76. The number of publications showed a three – fold increase over the study period compared
with less than two – fold increase in tuberculosis research during the same study period. Stratified by number
of publications, the United States of America ranked first while Switzerland ranked first in productivity per 100 million
people, and South Africa ranked first in productivity stratified per one trillion Gross Domestic Product. Three of the
High Burden Countries (HBC) MDR-TB (India, China, and South Africa) were present in top productive countries. High
percentage of international collaboration was seen among most HBC MDR-TB. Except for Plos One journal, most active
journals in publishing articles on MDR, XDR, TDR-TB were in infection – related fields and in general medicine. Top 20
cited articles were published in prestigious journal such as Lancet and New England Journal of Medicine. The themes in
top 20 cited articles were diverse, ranging from molecular biology, diagnostic tools, co-infection with HIV, and results of
new anti-TB drugs.
Conclusion: Publications on MDR, XDR and TDR – TB are increasing in the past decade. International collaboration was
common. Many low resourced African and Asian countries will benefit from research leading to new diagnostic and
screening technology of TB. The exchange of expertise, ideas and technology is of paramount importance in this field.
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Background
Tuberculosis (TB) is considered a top infectious disease
killer worldwide making it a major public health problem
[1, 2]. Global Tuberculosis Report, published by World
Health Organization (WHO), stated that in 2014, TB
killed 1.5 million people [3]. The year 2015 marked the
end of United Nations Millennium Development Goals
(MDGs) which was aimed at halting and reversing world-
wide TB, malaria and human immunodeficiency virus
(HIV). Despite the continuous and slow decline in TB,
there are still few challenges confronting the control of
TB. Association of TB with poverty, co-infection with
HIV, and emergence of TB drug resistance are major chal-
lenges for worldwide TB control [2]. Antimicrobial resist-
ance (AMR), in general, is a global challenge that
threatens the clinical benefit of many important anti-
microbial agents and requires an immediate action for
containment and reversal [4]. In case of TB, three serious
types of drug resistant TB have been identified: (1)
multidrug-resistant TB (MDR-TB) which is a TB with re-
sistance to at least isoniazid and rifampicin; (2) extensively
drug-resistant TB (XDR-TB), which is a form of MDR-TB
that is resistant to isoniazid and rifampin, plus any fluoro-
quinolone and at least one of three injectable second-line
drugs (i.e., amikacin, kanamycin, or capreomycin) [5, 6];
and finally, total drug-resistant TB (TDR) in which Myco-
bacterium tuberculosis strains are resistant to all first and
second line anti-TB agents [7–10].
In 2014, MDR-TB was responsible for the death of
190,000 people and it is predicted that if all TB cases
identified in 2014 were tested for drug resistance, a total
of 300,000 patients would carry MDR-TB. More than
half (54%) of these patients are living in India, China
and Russian Federation [3]. Treatment and control of
TB requires the availability of effective drug therapy
which in turn requires understanding the pattern of
growth and development of resistance of Mycobacterium
tuberculosis to first line drug therapy. The WHO has de-
veloped the concept of “High Burden Country” (HBC) to
emphasize the health burden and to facilitate the under-
standing of global TB burden post 2015 era. The HBC
MDR -TB list includes 20 HBC countries in terms of abso-
lute numbers of cases and an additional 10 countries with
the most severe burden in terms of case rates per capita
that do not already appear in the “top 20” [3, 11].
Research on drug resistance is a key element for future
planning to eliminate TB since the progress made on
halting TB in the past two decades could be undermined
by the development of drug-resistant Mycobacterium
tuberculosis [12]. This requires evaluation and analysis
of published research on resistant TB and where we
will stand on this issue in the future. Publications on
TB and the contribution of various countries to these
publications have been studied through bibliometric
studies [13–17]. However, no such studies, that the
author is aware of, have described the bibliometrics
of drug resistant TB in general and MDR, XDR, and
TDR-Tb in specific. In fact, one of the components of
Stop TB Strategy and End TB Strategy is intensified
research and innovation [3].
Bibliometrics is a statistical method used to analyze and
assess various aspects related to the topic of interest [18].
Such aspects include contribution of countries, core jour-
nals, most active researchers, international collaboration,
annual growth of publications, and top cited articles in the
field [19]. This study was carried out as an effort to shed
light on a challenging worldwide problem facing the fu-
ture target to end TB. The objective of this study was to
retrieve and analyze worldwide publications on MDR,
XDR and TDR-TB for the past decade (2006 – 2015). In
this study, bibliometric indicators for data extracted from
Scopus database will be presented and gaps pertaining to
knowledge about research activity on MDR, XDR and
TDR-TB will be filled.
Methods
The methodology used in this study has been described
in previously published bibliometric studies [20–28].
Several electronic databases can be used to carry out
bibliometric studies. Scopus database has been selected
to perform this study because it has several advantages
over other databases [29]. Scopus includes larger number
of journals than either Pubmed or Web of Science. Fur-
thermore, Scopus allows a wide range and more accurate
data analysis than either Pubmed or Google scholar [30].
In this study, data were retrieved using keywords in
article title to maximize accuracy of the results. The key-
words used in this study were obtained partially from
previous review articles on MDR-TB [31]. The use of
keywords in title-abstract search will yield a high percent-
age of false positive results. However, the use of keywords
in title search only will minimize false positive results.
Figure 1 shows a scheme that includes search queries used
and the number of retrieved articles in each step.
In search query shown in Fig. 1, the asterisk was used
after some keywords as a wild card to retrieve all words
relevant to the keyword of interest. The duration of
study was set from 2006 to 2015. The study period rep-
resents one decade. During this period reports of MDR,
XDR, and TDR-TB has emerged strongly. The retrieved
documents were limited to journal articles while books
and book chapters were excluded. No exclusion was
made based on language of the document.
The validity of search strategy was tested by manually
reviewing a random sample of 20% of retrieved articles.
Validity was confirmed when all randomly tested articles
were related to MDR, XDR or TDR-TB. The validation
test confirmed that there were minimum false positive
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results in retrieved documents. Three articles that were
false positive were excluded using the function “AND
NOT” as appeared in the search query (Fig. 1). However,
false negative results remain a possibility especially when
the search query was based on title search only. The au-
thor, with the help of experts in data management, tried
at least five different scenarios of search queries using
different search strategies, and the ultimate results in all
scenarios had large numbers of false positive results with
no significant addition of true articles on MDR, XDR,
and TDR-TB. Therefore, the use of the current search
query will avoid large numbers of false positive articles
but will miss very few true articles.
The growth of research on MDR, XDR, and TDR - TB
was presented graphically using Statistical Package for
Social Sciences (SPSS). The contribution of countries
and institutions/organizations was limited to top ten or
those with a minimum productivity of 20 articles. Prod-
uctivity of HBC TDR-TB was also presented. The stand-
ard competition ranking (SCR) was used to rank top ten
productive countries, institutions, and authors. Data per-
taining to productivity by countries was also stratified
with population size and Gross Domestic Product
(GDP). For each country, the total number of population
and GDP were obtained from World Bank website. To
calculate the productivity of each country stratified by
population size, we divided the number of publications
by the population size of that country. Similarly, to cal-
culate the productivity stratified by GDP, we divided the
number of publications by GDP of that country. For
population size, productivity was calculated per 100 mil-
lion inhabitants while for GDP, productivity was calcu-
lated per one trillion GDP.
Scopus can be used to provide analysis on inter-
national collaboration by counting number of articles
published by authors from the same country and articles
with authors from different countries. In other words,
there are two types of articles: single country publica-
tions (SCP) in which all authors belong to the same
country and such publications represent intra-country
collaboration; and multiple country publications (MCP)
in which authors belong to different countries and such
publications represent inter-country collaboration i.e.
international collaboration.
Quality of publications is difficult to measure or assess
directly. However, total number of citations received,
average number of citations per article, Hirsch-index
(h-index), percentage of highly cited articles, and im-
pact factor (IF) of journals can be used as an indirect
measure of publication impact or quality. H-index has
been developed to assess productivity and citation im-
pact of researchers. However, the use of h-index has
been extended to measure the productivity and citation
impact of countries and academic institutions [32]. In this
Fig. 1 Scheme showing steps of search strategy with keywords used and numbers of articles retrieved in each step
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study, h-indexes for countries and institutions were ob-
tained directly from Scopus database while IF was ob-
tained from Journal Citation Report 2015 published by
Thomson Reuters. To visualize country collaboration and
co-authorships, VOSviewer was used [33]. VOSviewer can
present information either as density visualizations or net-
work visualizations maps.
Ethical approval of this study was not required by IRB
since no human subjects or data were involved. All data
analysis was carried out on November 13th, 2016 to
avoid the dynamics of citations from 1 day to another.
Results
General information
Two thousand two hundred sixty journal articles were re-
trieved. The majority of retrieved documents were research
articles (1612; 71.3%). Other types of retrieved documents
are shown in Table 1. English (2047; 90.57%) was the most
commonly encountered language followed by Spanish
(49; 2.17%) and Chinese (45; 2.0%). The total number of ci-
tations received was 35,661 (mean ± SD = 7.04 ± 16.0; me-
dian (Q1-Q3) = 3(0–7)) while h-index was 76. The highest
number of publications was recorded in 2015 with a total
of 342, while the lowest number of publications was re-
corded in 2006 with a total number of 116. This represents
a threefold increase in number of publications. Figure 2
shows the growth of publications on the past four decades
while Fig. 3 shows the growth of publications on tubercu-
losis in general and on MDR, XDR, and TDR resistance in
particular in the past decade. The growth of publications
on TB showed less than two- fold increase in the past dec-
ade while the growth of publications on MDR, XDR, and
TDR – TB showed approximately three – fold increase.
Country analysis
Authors from 124 different countries contributed to re-
trieved documents. The United States of America (USA)
ranked first in the number of publications followed by
India, South Africa, and the United Kingdom (UK).
Table 2 shows the list of all countries that contributed to
publications. There was a total of 243 (10.7%) articles
with undefined affiliation. These articles include one or
more authors with missing country affiliation or country
affiliation of certain authors is not being updated by
Scopus system at the date of data analysis. Table 3 shows
the list of top 10 productive countries. The top 10 list in-
cluded five European countries plus the USA, India,
China, South Korea, and South Africa. Netherlands
ranked 11th and was outside the top 10 active list.
When top productive countries were stratified by
number of citations per article, Switzerland ranked first
followed by South Africa and Italy. Publications from
India and China had the lowest number of citations per
article. Articles produced by international collaboration
(MCP) had higher number of citations per article
compared with articles produced without international
collaboration (SCP). This indicates that international
collaboration is important in increasing number of cita-
tions. Interestingly, countries with the lowest percentage
of international collaboration, such as China and India,
had the lowest number of citations per article. When
data for top ten countries were stratified by population
size, Switzerland ranked first followed by South Africa
and the UK (Table 4). When data were stratified
based on GDP, South Africa ranked first followed by
Switzerland and India.
Visualization of international collaboration among
countries with a minimum productivity of twenty docu-
ments is shown in Fig. 4. Visualization map shows the ex-
tent and strength of international collaboration between
any two countries. The extent of international collabor-
ation for any country is assessed by the size of circle
assigned for that country while the strength of collabor-
ation between any two countries is assessed by the thick-
ness of the line connecting the two countries. Strong
collaborations were found between the following pairs of
countries: USA – South Africa (link strength = 109), USA
– Peru (link strength = 47), South Africa – UK (link
strength = 42), USA – Switzerland (link strength = 42),
USA – UK (link strength = 36), USA – Russian Federation
(link strength = 30). USA – South Korea (link strength =
26), USA – China (link strength = 24), USA – Latvia (link
strength = 25), and UK – Germany (link strength = 23).
Productivity from HBC MDR-TB
Three of HBC (India, China, and South Africa) were in
the top ten list. On the other hand, seven HBC (N. Korea,
Myanmar, Angola, Kyrgyzstan, Papua New Guinea,
Tajikistan, and Zimbabwe) had no contribution at all. The
remaining HBC (20 countries) were shown in Table 5.
The majority of contributing HBC MDR-TB had more
than 40% of their publications produced through inter-
national collaboration. The exception was Indonesia. The
total number of publications produced by HBC MDR-TB,
Table 1 Types of retreived documents (2006 – 2015)







Article in Press 27 1.19
Short Survey 22 0.97
Conference Paper 18 0.80
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including China, India, and South Africa, was 914 articles.
The growth of publications from HBC MDR-TB was al-
most parallel to worldwide productivity (Fig. 5). However,
the gap between the two curves get narrower with time
and the growth rate of publications from HBC MDR-TB
exceeded that of the worldwide productivity in the last
few years. This is due to research productivity from China,
India, and South Africa which are considered within the
HBC MDR-TB. In 2006, productivity from HBC MDR-TB
was almost one forth that of worldwide while in 2015 the
productivity of HBC MDR-TB became half that of world-
wide. Poisson regression model showed that productivity
from HBC MDR-TB was a significant predictor (p < 0.001)
of worldwide productivity. The model indicated that for
each article produced from HBC MDR-TB, the worldwide
productivity increased by 1.01.
Institutions/ Organizations
Top ten productive institutions/ organizations are
shown in Table 6. The WHO ranked first followed by
Fig. 2 Growth of publications on MDR, XDR and TDR-TB in the past four decades
Fig. 3 Growth of worldwide publications on TB and on MDR, XDR, TDR-TB during the past decade
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Centers for Disease Prevention and Control (CDC)
and Harvard Medical School. The total productivity
from Harvard Medical School and Harvard School of
Public Health was 98 articles which is greater than
that of CDC and lower than that of WHO. The top
list included five American institutions/ organizations,
three South African, two Italian, and one international
organization (WHO). The impact of publications from
top ten productive institutions/ organizations was assessed
indirectly by the percentage of highly cited articles for
each institutions/ organization. Albert Einstein College of
Medicine of Yeshiva University (USA) ranked first in the
percentage of highly cited articles followed equally by the
two Italian institutions, Università degli Studi di Sassari,
and IRCCS Fondazione Salvatore Maugeri.
Journals
Journals publishing at least 20 articles on MDR, XDR,
TDR-TB are shown in Table 7. The total number of pub-
lications produced by journals in the list was 975









USA 517 22.88 Argentina 29 1.28 Zambia 7 0.31 Azerbaijan 2 0.09
India 269 11.90 Belarus 19 0.84 Austria 6 0.27 Central African
Republic
2 0.09
South Africa 229 10.13 Denmark 19 0.84 Burkina Faso 6 0.27 Cuba 2 0.09
UK 186 8.23 Viet Nam 18 0.80 Cote d’Ivoire 6 0.27 Ecuador 2 0.09
China 158 6.99 Georgia 15 0.66 Lesotho 6 0.27 Jamaica 2 0.09
France 122 5.40 Poland 15 0.66 Botswana 5 0.22 Mozambique 2 0.09
Switzerland 117 5.18 Colombia 14 0.62 Bulgaria 5 0.22 Palestine 2 0.09
South Korea 102 4.51 Czech
Republic
13 0.58 Cambodia 5 0.22 Sudan 2 0.09
Italy 100 4.42 Ethiopia 13 0.58 Chile 5 0.22 Swaziland 2 0.09
Germany 91 4.03 Romania 13 0.58 Egypt 5 0.22 Tunisia 2 0.09
Netherlands 85 3.76 Bangladesh 12 0.53 Guadeloupe 5 0.22 Venezuela 2 0.09
Spain 73 3.23 Singapore 12 0.53 Haiti 5 0.22 Albania 1 0.04
Peru 69 3.05 Malaysia 11 0.49 Lithuania 5 0.22 Croatia 1 0.04
Iran 64 2.83 Gambia 10 0.44 Mongolia 5 0.22 Djibouti 1 0.04
Belgium 62 2.74 Hungary 10 0.44 Congo 4 0.18 Dominican
Republic
1 0.04
Japan 61 2.70 Namibia 10 0.44 Iceland 4 0.18 Micronesia 1 0.04
Sweden 56 2.48 Uganda 10 0.44 Ireland 4 0.18 French Guiana 1 0.04
Brazil 51 2.26 Ukraine 10 0.44 Kazakhstan 4 0.18 Ghana 1 0.04
Russian
Federation
51 2.26 Kuwait 9 0.40 New Zealand 4 0.18 Guinea-Bissau 1 0.04
Portugal 48 2.12 Moldova 9 0.40 Algeria 3 0.13 Jordan 1 0.04
Australia 44 1.95 Nigeria 9 0.40 Armenia 3 0.13 Laos 1 0.04
Pakistan 43 1.90 Saudi Arabia 9 0.40 Benin 3 0.13 Lebanon 1 0.04
Taiwan 42 1.86 Greece 8 0.35 Cameroon 3 0.13 Oman 1 0.04
Thailand 40 1.77 Nepal 8 0.35 Finland 3 0.13 Puerto Rico 1 0.04
Mexico 36 1.59 Norway 8 0.35 Gabon 3 0.13 Rwanda 1 0.04
Canada 35 1.55 Tanzania 8 0.35 Honduras 3 0.13 Saint Kitts
and Nevis
1 0.04
Estonia 32 1.42 Indonesia 7 0.31 Iraq 3 0.13 Slovenia 1 0.04
Latvia 32 1.42 Israel 7 0.31 Madagascar 3 0.13 Somalia 1 0.04
Turkey 32 1.42 Kenya 7 0.31 Malawi 3 0.13 Togo 1 0.04
Philippines 31 1.37 Luxembourg 7 0.31 Morocco 3 0.13 UAE 1 0.04
Hong Kong 30 1.33 Uzbekistan 7 0.31 Panama 3 0.13 Undefined 243 10.75
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(43.14%) with a total IF of 7494.27 which gives an aver-
age of 7.68 per article. The International Journal of
Tuberculosis and Lung Diseases ranked first followed
by PloS One. Most journals in the list have IF. PloS
One journal was the only multidisciplinary journal
present in the list. The other ones in the list were
within the scope of infection and general medicine.
Lancet and New England Journal of Medicine (NEJM)
had the highest IF and both are in general medicine.
The top list included one Chinese and one Japanese
journal while the remaining journals are Europeans or
American ones.
Citation analysis of most productive journals is depicted
as a network visualization map (Fig. 6). International
Table 3 Top ten productive countries along with their international collaboration and citation analysis (2006–2015)
SCR Country Frequency %
N = 2260
TC C/A h-index NCC SCP % TC C/A h-index MCP % TC C/A h-index
1st USA 517 22.88 15,483 29.95 61 75 147 28.43 3153 21.45 30 370 71.57 12,330 33.32 52
2nd India 269 11.90 3341 12.42 29 39 216 80.30 1805 8.36 21 53 19.70 1536 28.98 18
3rd S. Africa 229 10.13 8380 36.59 40 50 45 19.65 555 12.33 12 184 80.35 7825 42.53 39
4th UK 186 8.23 4608 24.77 33 69 38 20.43 336 8.84 11 148 79.57 4272 28.86 33
5th China 158 6.99 1460 9.24 19 30 110 69.62 713 6.48 16 48 30.38 747 15.56 13
6th France 122 5.40 3116 25.54 25 74 33 27.05 327 9.91 9 89 72.95 2789 31.34 24
7th Switzerland 117 5.18 5766 49.28 37 63 22 18.80 1015 46.14 10 95 81.20 4751 50.01 33
8th S. Korea 102 4.51 3004 29.45 25 37 73 71.57 1161 15.90 19 29 28.43 1843 63.55 15
9th Italy 100 4.42 3515 35.15 32 52 25 25.00 199 7.96 9 75 75.00 3316 44.21 31
10th Germany 91 4.03 2837 31.18 28 55 21 23.08 132 6.29 5 70 76.92 2705 38.64 22
SCR standard competition rank
TC total citations
C/A number of citations per article. It is calculated by dividing the total number of citations by total number of publications retrieved for the assigned country
NCC number of collaborating countries
SCP single country publications (intra country collaboration)
MCP multiple country publications (inter country collaboration)
h-index Hirsh index
USA United States of America
UK United Kingdom
S. Africa South Africa
S. Korea South Korea
Table 4 Productivity of top ten active countries stratified by population size and GDP




Number of articles per
100 million populationa(R)
GDP in trillions Number of articles per
one trillion GDPb (R)
1st USA 517 22.88 321.4 160.86 (7) 17.95 28.80 (9)
2nd India 269 11.90 1311 20.52 (9) 2.074 131.41 (3)
3rd S. Africa 229 10.13 54.96 416.67 (2) 0.3128 731.63 (1)
4th UK 186 8.23 65.14 285.54 (3) 2.849 65.29 (4)
5th China 158 6.99 1371 11.52 (10) 10.87 14.54 (10)
6th France 122 5.40 66.81 182.61 (5) 2.422 50.37 (7)
7th Switzerland 117 5.18 8.287 1411.85 (1) 0.6647 175.94 (2)
8th S. Korea 102 4.51 50.81 200.79 (4) 1.929 55.19 (5)
9th Italy 100 4.42 60.80 164.47 (6) 1.815 55.10 (6)
10th Germany 91 4.03 81.41 111.78 (8) 3.356 27.12 (8)
SCR Standard competition rank
USA United States of America
UK United Kingdom
S. Africa South Africa
S. Korea South Korea
R rank
GDP Gross Domestic Product
MDR, XDR, and TDR-TB multi-, extensively, and totally drug resistant tuberculosis
acalculated by dividing number of publications for a particular country by its population size then multiplying by 100
bcalculated by dividing the number of publications of a particular country by its GDP in trillions
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Journal of Tuberculosis and Lung Disease had the highest
number of citations followed by PloS One and European
Respiratory Journal. The number of citations is correlated
with the circle size assigned for the journal. Co-citation
analysis for most productive journals is shown in Fig. 7.
Journals with a minimum of 200 citations were included.
International Journal of Tuberculosis and Lung Disease is
commonly co-cited with Lancet (link strength = 6842),
Journal of Clinical Microbiology (link strength = 5767),
Antimicrobial Agents and Chemotherapy (link strength =
5052), NEJM (link strength = 5161), Clinical Infectious Dis-
ease (link strength = 4882), and American Journal of Re-
spiratory and Critical Care Medicine (link strength = 4515).
Authors
A total of 8246 authors contributed to the publications,
giving an average of 3.65 authors per article. Authors
who had published at least 20 articles are shown in
Table 8. The list included five authors from the USA,
three authors from Italy, three authors from Iran, two
authors from South Africa, two from WHO, one from
China, one from Latvia, one from Germany, one from
Switzerland, one from Sweden, and one with two affilia-
tions, USA/ UAE. Author collaboration among top ac-
tive authors is depicted in Fig. 8. Examples of strong
collaboration were seen among the following authors:
Migliori, G.B. - Sotgiu, G. (link strength = 37), Migliori,
G.B. - Centis, R. (link strength = 37), Mitnick, C.D. -
Becerra, M.C. (link strength = 22), Migliori, G.B. - Lange,
C. (link strength = 22), Sotgiu, G. - Centis, R. (link
strength = 25), Mitnick, C.D. - Bayona, J. (link strength =
16), and Masjedi, M.R. - Farnia, P. (link strength = 17).
The strength of collaboration is relative to the thickness
of connection between any two researchers. Authors
with similar circle color are considered a cluster, i.e. have
close collaboration.
Highly cited articles
Table 9 shows the top 20 highly cites articles. The high-
est number of citations obtained was 1069. The article
titled “Extensively drug-resistant tuberculosis as a cause
of death in patients co-infected with tuberculosis and
HIV in a rural area of South Africa” received the highest
number of citations. Four articles from the top 20 cited
articles were published in NEJM, three articles were pub-
lished in Lancet, and two were published in Lancet Infec-
tious Diseases. The topics covered in highly cited articles
range from general public health impact of MDR, XDR,
TDR-TB to results of newly approved drugs for treat-
ment of MDR-TB. The top 20 cited articles included five
review articles, one conference paper, one letter, one
short survey, and the remaining were research articles.
Discussion
In this study, a bibliometric overview of publications on
MDR, XDR, and TDR-TB was presented. Our study
showed a steady increase on worldwide publications on
MDR, XDR and TDR-TB suggesting that this problem is
a global health problem and can be a public health bur-
den if the current situation continues as is [34, 35]. The
value of h-index of retrieved articles in the past decade
supports the fact that this problem is spreading and is
being cited heavily in the literature. Analysis of Scopus
database for articles with keywords pertaining to infec-
tious diseases showed six fold increase in the number of
publications from 2006 to 2015. Therefore, it is possible
Fig. 4 Network visualization map of country co-authorships. Legend: Countries with a minimum of 20 published articles were included. The map
includes 32 countries in three clusters. Number of co-authorships was highest for the USA followed by South Africa and the UK. Strong collaborations
were found between the following pairs of countries: USA – South Africa (link strength = 109), USA – Peru (link strength = 47), South Africa – UK (link
strength = 42), USA – Switzerland (link strength = 42), USA – UK (link strength = 36), USA – Russian Federation (link strength = 30). USA – South Korea (link
strength = 26), USA – China (link strength = 24), USA – Latvia (link strength = 25), and UK – Germany (link strength = 23)
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that part of the increase in MDR, XDR, and TDR-TB
publications is due to the overall growth of publications
with time in the field of infections and infectious dis-
eases. However, analysis of Scopus database for publica-
tions in the past decade showed that the number of
publications on TB was less than doubled in the past
decade while the number of publications on TB resist-
ance had increased by more than three folds in the past
decade suggesting that resistance is increasing at a rate
higher than that of TB in general.
According to Global Tuberculosis Report 2015, a total
of approximately 10 million incident cases of TB were
recorded in 2014, mostly in Asia and Africa [3, 36]. This
explains the presence of China, India, South Korea and
South Africa in the top ten productive countries. A
study in China found that 25% of surveyed TB patients
had TB that was resistant to isoniazid, rifampin, or both,
and 1 out of 10 had MDR tuberculosis [37]. Reports
from India about MDR, XDR and TDR –TB have been
published that raises calls of immediate response by In-
dian medical community [38]. South Africa has also re-
ported many cases of MDR, XDR and TDR-TB [39, 40].
The Global Tuberculosis Report further explains that 11–
13% of new incident tuberculosis cases in 2014 were
among HIV positive people. This might explain the pres-
ence of two articles in the most cited list that discuss tu-
berculosis and MDR in HIV patients. Actually, a study has
reported that tuberculosis, drug abuse, HIV, and MDR-TB
are devastating epidemics in some countries in Asia and
urgent action is needed [41]. Our study showed that three
countries of HBC MDR-TB ranked among the top ten ac-
tive countries. In general, the publication from HBC
MDR-TB was parallel to that of worldwide productivity
suggesting that there is a real interest and concern
Table 5 Productivity of HBC MDR-TB along with their citation analysis and international collaboration
Countrya Frequency (%)
N = 2260
TC C/A h-index NCC SCP % of SCP MCP % of MCP
Top HBC MDR-TB countries by estimated absolute number (in alphabetical order)
Bangladesh 12 0.53 294 24.50 6 7 5 41.67 7 58.33
DR Congo 4 0.18 9 2.25 2 5 0 0.00 4 100.00
Ethiopia 13 0.58 172 13.23 6 6 7 53.85 6 46.15
Indonesia 7 0.31 14 2.00 2 5 5 71.43 2 28.57
Kazakhstan 4 0.18 9 2.25 1 1 0 0.00 4 100.00
Kenya 7 0.31 309 44.14 4 14 2 28.57 5 71.43
Mozambique 2 0.09 295 147.50 2 5 0 0.00 2 100.00
Nigeria 9 0.40 32 3.56 3 9 4 44.44 5 55.56
Pakistan 43 1.90 283 6.58 11 29 25 58.14 18 41.86
Philippines 31 1.37 1705 55.00 14 33 5 16.13 26 83.87
Russian F. 51 2.26 1983 38.88 23 36 8 15.69 43 84.31
Thailand 40 1.77 815 20.38 12 29 18 45.00 22 55.00
Ukraine 10 0.44 61 6.10 6 18 3 30.00 7 70.00
Uzbekistan 7 0.31 189 27.00 5 11 0 0.00 7 100.00
Viet Nam 18 0.80 514 28.56 8 28 3 16.67 15 83.33
Countries with the highest number of TB case rates per capita
Azerbaijan 2 0.09 443 221.50 1 9 0 0.00 2 100.00
Belarus 19 0.84 469 24.68 9 33 0 0.00 19 100.00
Peru 69 3.05 2501 36.25 21 28 9 13.04 60 86.96
Moldova 9 0.40 108 12.00 7 22 0 0.00 9 100.00
Somalia 1 0.04 8 8.00 1 3 0 0.00 1 100.00
HBC MDR-TB High Burden Countries with Multidrug Resistant Tuberculosis
TC total citations
C/A average number of citations per article. It is calculated by dividing the total number of citations by total number of publications retrieved for the
assigned country
NCC number of collaborating countries
SCP single country publications (intra country collaboration)
MCP multiple country publications (inter country collaboration)
h-index Hirsh index
aCountries were listed alphabetically. Countries that were listed in top ten list were not listed in this table: China, India, and South Africa. The following countries
have zero contribution: N. Korea, Myanmar, Angola, Kyrgyzstan, Papua New Guinea, Tajikistan, Zimbabwe
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regarding this subject. Out of the twenty HBC MDR-TB,
Russian Federation and Peru had noticeable contribution.
Russian Federation is considered by the WHO as one of
30 countries described as HBC TB [42].
International collaboration was common among most
countries in the top productive countries. Despite that
initiation of successful collaboration between Western
rich countries and some poor countries with high TB
prevalence has been reported [43], countries like China,
India and South Korea where TB and TB-resistant cases
are found showed lower international collaboration in
TB drug resistance research. It could be the language
barrier particularly for Chinese and Korean scientists.
Other possible explanations include lack of collaboration
between these countries and European and American
countries in most other medical research fields. Collab-
oration among authors in different countries is import-
ant in advancing science and in combating TB through
exchange of expertise and knowledge. A study indicated
that public – private collaboration can produce success-
ful detection and therapy of TB cases [44]. Another
study indicated that governmental – NGOs collaboration
in poor countries like Bangladesh is an effective strategy
in detection and eradication of TB [45]. Antimicrobial
Fig. 5 Growth of publications from HBC MDR-TB (green line) compared with worldwide productivity (2006–2015). Key: Green line: HBC MDR-TB
productivity. Blue line: Worldwide productivity
Table 6 Top ten active institutions/ organizations in MDR, XDR, and TDR-TB publications (2006–2015)
SCRa Institution/ Organization Country Frequency %
N = 2260
HCA % of HCAb
1st Organisation Mondiale de la Sante WHO 104 4.60 35 33.65
2nd Centers for Disease Control and Prevention CDC (USA) 89 3.94 31 34.83
3rd Brigham and Women’s Hospital USA 74 3.27 18 24.32
4th Harvard Medical School USA 73 3.23 20 27.40
5th Universiteit Stellenbosch S. Africa 61 2.70 23 37.70
6th University of Cape Town S. Africa 54 2.39 16 29.63
7th Albert Einstein College of Medicine of Yeshiva University USA 44 1.95 25 56.82
8th South African Medical Research Council S. Africa 43 1.90 17 39.53
9th Universita degli Studi di Sassari Italy 42 1.86 18 42.86
9th IRCCS Fondazione Salvatore Maugeri Italy 42 1.86 18 42.86
9th Partners in Health USA 42 1.86 12 28.57
aSCR: standard competition rank. Equal countries were given the same ranking number, and then a gap is left in the ranking numbers
bHCA: number of highly cited articles. Articles with ≥ 30 citations were considered HCA. Percentage of HCA was calculated by dividing total number of HCA by
total number of publications for each institution/ organization assigned
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Table 7 Journals publishing at least 20 articles on MDR, XDR, and TDR – TB (2006–2015)
Journal Country Frequency % IF TIF
International Journal of Tuberculosis and Lung Disease France 212 9.38 2.315 490.78
Plos One USA 123 5.44 3.54 435.42
European Respiratory Journal Switzerland 81 3.58 8.332 674.892
Emerging Infectious Diseases USA 61 2.70 6.99 426.39
Journal of Clinical Microbiology USA 54 2.39 3.993 215.622
Clinical Infectious Diseases USA 50 2.21 8.736 436.8
Antimicrobial Agents and Chemotherapy USA 41 1.81 3.34 136.94
Lancet UK 41 1.81 44.002 1804.082
Journal of Antimicrobial Chemotherapy UK 38 1.68 4.919 186.922
BMC Infectious Diseases UK 37 1.64 2.690 99.53
International Journal of Mycobacteriology USA 37 1.64 N/A 0
Indian Journal of Tuberculosis India 30 1.33 N/A 0
Lancet Infectious Diseases UK 27 1.19 21.371 577.017
American Journal of Respiratory and Critical Care Medicine USA 26 1.15 13.118 341.068
International Journal of Antimicrobial Agents Netherlands 26 1.15 4.079 106.054
New England Journal of Medicine USA 25 1.11 59.558 1488.95
Tuberculosis USA 25 1.11 2.952 73.8
Kekkaku Japan 21 0.93 N/A 0
Chinese Journal of Tuberculosis and Respiratory Diseases China 20 0.88 N/A 0
975 (43.14%) 7494.267
IF impact factor
TIF total impact factor obtained by multiplying the impact factor of the journal by the number of articles published by that journal = 7494.267
Fig. 6 Network visualization map of journal citations. Legend: Journals with a minimum of 20 articles published on MDR, XDR, TDR-TB were
included. International Journal of Tuberculosis and Lung Disease had the highest number of citations followed by European Respiratory Journal
and PloS One. The number of citations is correlated with the circle size assigned for the journal
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Fig. 7 Journal co-citation analysis. Legend: Journals with a minimum of 200 citations were included. Twenty journals are shown in the network
visualization map to make the map readable and less crowded. International Journal of Tuberculosis and Lung Disease is commonly co-cited with
Lancet (link strength = 6842), Journal of Clinical Microbiology (link strength = 5767), Antimicrobial Agents and Chemotherapy (link strength = 5052),
NEJM (link strength = 5161), Clinical Infectious Disease (link strength = 4882), and American Journal of Respiratory and Critical Care Medicine
(link strength = 4515)
Table 8 Top active authors with a minimum contribution of 20 articles (2006 – 2015)
Author Frequency %
N = 2260
Affiliation as appeared in Scopus profile
Migliori, G.B. 63 2.79 IRCCS Fondazione Salvatore Maugeri, Pavia, Italy
Mitnick, C.D. 36 1.59 Partners in Health, Boston, United States
Sotgiu, G. 42 1.86 Universita degli Studi di Sassari, Department of Biomedical Sciences, Sassari, Italy
Becerra, M.C. 29 1.28 Harvard Medical School, Department of Global Health and Social Medicine, Boston, United States
Keshavjee, S. 31 1.37 Harvard Medical School Center for Global Health Delivery, Dubai, United Arab Emirates
Centis, R. 39 1.73 IRCCS Fondazione Salvatore Maugeri, Pavia, Italy
Bayona, J. 25 1.11 Harvard Medical School, Department of Global Health and Social Medicine, Boston, United States
Farnia, P. 25 1.11 Shahid Beheshti University of Medical Sciences, Tehran, Iran
Gandhi, N.R. 27 1.19 Rollins School of Public Health, Atlanta, United States
Leimane, V. 26 1.15 Riga East University Hospital, Riga, Latvia
Masjedi, M.R. 25 1.11 Shahid Beheshti University of Medical Sciences, Chronic Respiratory Disease Research Center, Tehran, Iran
Yew, W.W. 26 1.15 Chinese University of Hong Kong, Stanley Ho Centre for Emerging Infectious Diseases, Hong Kong, China
Zignol, M. 24 1.06 Organisation Mondiale de la Sante, Global TB Programme, Geneve, Switzerland
Lange, C. 27 1.19 Forschungszentrum Borstel - Zentrum fur Medizin und Biowissenschaften, Borstel, Germany
Padayatchi, N. 25 1.11 Centre for the AIDS Programme of Research in South Africa, Congella, South Africa
Tabarsi, P. 23 1.02 Shahid Beheshti University of Medical Sciences, Tehran, Iran
Victor, T.C. 20 0.88 Universiteit Stellenbosch, Division of Molecular Biology and Human Genetics, Stellenbosch, South Africa
Koh, W.J. 22 0.97 SungKyunKwan University, School of Medicine, Department of Medicine, Suwon, South Korea
D’Ambrosio, L. 20 0.88 Public Health Consulting Group, Lugano, Switzerland
Falzon, D. 20 0.88 Organisation Mondiale de la Sante, Global TB Programme, Geneve, Switzerland
Hoffner, S. 20 0.88 Karolinska University Hospital, Department of Microbiology, Tumor and Cell Biology, Stockholm, Sweden
Shah, N.S. 20 0.88 Albert Einstein College of Medicine of Yeshiva University, Department of Medicine, New York, United States
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resistance is a true challenge for international efforts to
stop and reverse TB worldwide [46]. Preparing for this
challenge requires collaboration, use of advanced molecu-
lar biology techniques, development of new pharmaceuti-
cals, and worldwide research activity on TB.
Exploration of the top ten cited articles on MDR, EDR
and TDR-TB reveals much to be planned for in this re-
gard. It is true that TB is a major single killer among all
infectious diseases, but co-infection of TB with HIV
makes the prognosis even worse which requires the
availability of potent anti-TB drugs and combating de-
velopment of resistance to these drugs to promote better
prognosis for patients co-infected with HIV and TB.
Some authors described the presence of HIV and MDR-
TB as a perfect storm with disastrous consequences
[47]. Effective diagnostic tools for screening and early
detection of TB and MDR-TB is an important strategy
in combating drug resistant TB [48, 49]. The develop-
ment of such cost-effective diagnostic techniques is ur-
gent given that the majority of TB patients have no
access to drug-resistance screening to optimize their
therapy [49]. No wonder that an article about the feasi-
bility and efficacy of a diagnostic techniques was among
top ten cited articles [48]. One more important of con-
cern in drug – resistant TB global public health chal-
lenge is the search for new drugs to overcome reported
MDR-TB. One such drug is diarylquinoline TMC207
which is still under clinical investigation for MDR-TB
cases [50].
No doubt that drug resistance TB deserves a lot of re-
search and the scientific community needs to be aware
where worldwide research on this topic is standing. Our
Fig. 8 Network visualization for author co-authorships (collaboration). Legend: Authors with a minimum productivity of 20 articles were included.
Examples of strong collaboration were seen among the following authors: Migliori, G.B. - Sotgiu, G. (link strength = 37), Migliori, G.B. - Centis, R. (link
strength = 37), Mitnick, C.D. - Becerra, M.C. (link strength = 22), Migliori, G.B. - Lange, C. (link strength = 22), Sotgiu, G. - Centis, R. (link strength = 25),
Mitnick, C.D. - Bayona, J. (link strength = 16), and Masjedi, M.R. - Farnia, P. (link strength = 17). The strength of collaboration is relative to the thickness
of connection between any two researchers. Authors with similar circle color are considered a cluster, i.e. have close collaboration
Table 9 Top highly cited articles on MDR, XDR, TDR-TB (2006–2015)
Reference Number of citations Document Type Reference Number of citations Document Type
[53] 1069 Article [54] 264 Article
[55] 587 Review [56] 262 Article
[57] 443 Article [58] 261 Article
[59] 435 Review [60] 257 Short Survey
[61] 424 Article [62] 253 Letter
[63] 374 Article [64] 246 Review
[65] 340 Article [66] 236 Article
[67] 297 Review [68] 226 Article
[7] 290 Article [69] 219 Article
[70] 284 Conference Paper [71] 214 Review
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study is being strong in the fact that it is the first to give
a bibliometric overview on MDR, XDR and TDR – TB
publications. However, missing some articles is a possi-
bility due to unindexed journal publication or accuracy
of search strategy despite that the authors have done
their best to avoid false negative and false positive results
as described in the methodology. Furthermore, the use
of title search strategy instead of title/abstract strategy
created some pros and cons. Title search strategy cre-
ated minimum false positive results, but might create
some false negative results that need to be taken into
consideration. No bibliometric study is 100% accurate
and perfect and it is always a snapshot of the current
situation based on certain keywords used in data collec-
tion. In addition, no electronic database is considered
perfect for data collection. System updates, different af-
filiations, different name spelling, and sometimes miss-
ing data can be found in electronic databases commonly
used in bibliometric studies. Finally, it should be empha-
sized that definitions pertaining to resistance termin-
ology are not standardized. However, the definitions
presented in this study are the most common ones. Lim-
itations in this study are similar in nature to those
present and listed in most bibliometric studies [21–28].
Despite all these limitations, this study was meant to fill
gap in literature and knowledge on MDR, XDR, and
TDR –TB in general hoping that this study will be of
value to those in the field. Furthermore, this is the first
bibliometric study on MDR, XDR, and TDR-TB despite
that several bibliometric studies on TB were carried out
[51, 52].
Conclusions
Our study showed that publications on MDR, XDR and
TDR – TB have increased in the past decade. The major-
ity of articles on MDR, XDR and TDR-TB were published
in journals with high IF, suggestive of importance of the
topic to clinicians and researchers. Search for feasible, ac-
curate, cost effective diagnostic tests, and new anti TB
drugs are hot topics in this field. International collabor-
ation in this field was evident for most countries. The ex-
change of expertise, ideas and technology is of paramount
importance in this field especially that TB is common in
poor countries that lack these expertise.
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